Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entrectinib versus crizotinib in ROS1-positive advanced or metastatic non-small cell lung cancer
NL-OMON60250Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Entrectinib with Crizotinib (2 arms). Primary endpoint: Progression-free survival in patients with CNS metastases at baseline. Started Nov 2021; status: active, not recruiting.
02
Drugs
entrectinibcrizotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON60250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60250.